Loomis, Sayles & Company
TNDM icon

Loomis, Sayles & Company’s Tandem Diabetes Care TNDM Stock Holding History

Loomis, Sayles & Company’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400
Closed -$12K – 947
2023
Q4 		$12K Buy
+400
New +$8.3K ﹤0.01% 753
2023
Q3 		– Sell
-79
Closed -$2K – 1020
2023
Q2 		$2K Buy
+79
New +$2.54K ﹤0.01% 951
2022
Q4 		– Sell
-18
Closed -$1K – 978
2022
Q3 		$1K Hold
18
– – ﹤0.01% 928
2022
Q2 		$1K Sell
18
-3
-14% -$246 ﹤0.01% 952
2022
Q1 		$2K Buy
+21
New +$2.45K ﹤0.01% 974
2021
Q1 		– Sell
-117
Closed -$11K – 894
2020
Q4 		$11K Buy
+117
New +$12.1K ﹤0.01% 719

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Loomis, Sayles & Company's TNDM Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Tandem Diabetes Care (TNDM) in Q1 2024, closing a stake of 400 shares — an estimated $12K sold.

Loomis, Sayles & Company first reported a position in TNDM in Q4 2020 and held it in 6 quarters. The position peaked at $12K in Q4 2023. 291 funds tracked by Wall St. Rank hold TNDM as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Tandem Diabetes Care position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 400 Tandem Diabetes Care shares in Q1 2024, an estimated $12K.
  • Loomis, Sayles & Company first reported a position in Tandem Diabetes Care in Q4 2020 and held it in 6 quarters.
  • Loomis, Sayles & Company's Tandem Diabetes Care position peaked at $12K in Q4 2023.
  • 291 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.